Physician profile
Ronald Smith
NPI 1215927124
$4,084.77
in general payments reported to CMS, 2019-2025
17 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $109 · 2021: $527 · 2022: $754 · 2023: $329 · 2024: $877 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,064.00 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $463.86 | 2019-2024 | Mounjaro |
| Abbvie INC. | $413.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.85 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $238.66 | 2019-2021 | |
| Merz North America, INC. | $231.24 | 2022 | |
| Edwards Lifesciences Corporation | $219.52 | 2024-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $193.71 | 2019 | |
| Glaxosmithkline, LLC. | $160.33 | 2023 | Arexvy |
| Abbott Laboratories | $149.44 | 2024 | Mitraclip |
| Alnylam Pharmaceuticals INC. | $124.99 | 2024 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $124.37 | 2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $118.47 | 2019 | |
| Amgen INC. | $103.99 | 2019 | |
| Ascendis Pharma Endocrinology INC | $76.96 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $19.70 | 2024 | Doc Band |
| Ferring Pharmaceuticals INC. | $15.58 | 2023 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.